Acute Myeloid Leukemia

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the global phase 3 MIRACLE trial.

As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety and antileukemic activity.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

We, survivors, often express our gratitude for life, love, support and research, but what about the patients who do not experience positive outcomes from treatment?

During this holiday season, I wanted to take a moment and reflect on how my dog Payton stayed by my side during acute myeloid leukemia.

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.

During the holiday season, overwhelming feelings are OK to have, whether you are a patient with cancer or a caregiver.

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

Adjusted survival outcomes were similar for patients with NPM1-mutated AML with intensive induction chemotherapy or hypomethylating agents and Venclexta.

During my second trimester of pregnancy, I started to notice a weird rash, which led to other events before my diagnosis of AML.

As a survivor of acute myeloid leukemia, some things are no longer going to be normal, but who wants to be normal?

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were available to me.

While spending weeks in the hospital for acute myeloid leukemia, I tried eight fun things to keep me busy.

Researchers compared health-related quality of life among patients ages 60 and older with acute myeloid leukemia undergoing different chemotherapy regimens.

After receiving cancer treatment and leaving the hospital, sometimes it feels like a safety net has been pulled away and loneliness sets in.

Being able to live independently and enjoy life’s beauty summon feelings of gratitude and euphoria more often now.

Patients aged 80 and older are often excluded from receiving the standard regimen for acute myeloid leukemia. However, research showed that some patients can tolerate the therapy.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.

From Fortnight player, “Ninja” announcing his melanoma diagnosis to an LSU quarterback sporting the name of his teammate with brain cancer, here’s what’s going on in the oncology space this week.

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

I recently heard a story about a patient's personality change because of cancer, and it reminded me of the hyperactive delirium I experienced.

A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML.

Newly diagnosed patients with FLT3-mutated acute myeloid leukemia showed improvements after receiving crenolanib plus chemotherapy in a recent study.

As a comfort care companion for Moffitt Cancer Center, I sat vigil next to a dying patient with cancer with no family.